General market puked last week and investors will likely be rethinking longer term allocations.
Health Care and Pharma usually a beneficiary of thos defensive environment. Bot is a spec yes. but woth SB it is a when not if scenario.
This is a opportune time for a bigger player to make a move as the potential earnongs are not priced in to the sp.
Doubt Mgt would want a buyout at this price or timeframe but it may be in the cards.
Ann: BOT Submits FDA New Drug Application for Sofpironium Bromide, page-17
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 34.3¢ | $2.809M | 7.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 57034 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 299631 | 5 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |